• Gene deletion; HGNC; HGNC:7765; NF1; Zygosity=Heterozygous (PubMed=15207265).
  
• Gene deletion; HGNC; HGNC:11998; TP53; Zygosity=Heterozygous (PubMed=15207265).
  
• Mutation; HGNC; HGNC:7765; NF1; Simple; p.Tyr2285Ter (c.6792C>A); ClinVar=VCV000185082; Zygosity=Heterozygous (PubMed=15207265; DepMap=ACH-002693).
  
• Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg110Pro (c.329G>C); ClinVar=VCV000233627; Zygosity=Heterozygous (PubMed=21084276; DepMap=ACH-002693).
  

PubMed=15207265; DOI=10.1016/j.nbd.2004.01.006
Frahm S., Mautner V.-F., Brems H., Legius E., Debiec-Rychter M., Friedrich R.E., Knoefel W.T., Peiper M., Kluwe L.
Genetic and phenotypic characterization of tumor cells derived from malignant peripheral nerve sheath tumors of neurofibromatosis type 1 patients.
Neurobiol. Dis. 16:85-91(2004)

PubMed=15735744; DOI=10.1038/sj.onc.1208425
Mashour G.A., Drissel S.N., Frahm S., Farassati F., Martuza R.L., Mautner V.-F., Kindler-Rohrborn A., Kurtz A.
Differential modulation of malignant peripheral nerve sheath tumor growth by omega-3 and omega-6 fatty acids.
Oncogene 24:2367-2374(2005)

PubMed=18650488; DOI=10.1215/15228517-2008-053; PMCID=PMC2719009
Holtkamp N., Malzer E., Zietsch J., Okuducu A.F., Mucha J., Mawrin C., Mautner V.-F., Schildhaus H.-U., von Deimling A.
EGFR and erbB2 in malignant peripheral nerve sheath tumors and implications for targeted therapy.
Neuro-oncol. 10:946-957(2008)

PubMed=21084276; DOI=10.1158/0008-5472.CAN-10-2799; PMCID=PMC3064267
Lopez G., Torres K.E., Liu J.J.-H., Hernandez B., Young E.D., Belousov R., Bolshakov S.V., Lazar A.J.F., Slopis J.M., McCutcheon I.E., McConkey D.J., Lev D.C.
Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors.
Cancer Res. 71:185-196(2011)

PubMed=21695156; DOI=10.1371/journal.pone.0021099; PMCID=PMC3113907
Spyra M., Kluwe L., Hagel C., Nguyen R., Panse J., Kurtz A., Mautner V.-F., Rabkin S.D., Demestre M.
Cancer stem cell-like cells derived from malignant peripheral nerve sheath tumors.
PLoS ONE 6:E21099-E21099(2011)

PubMed=23437333; DOI=10.1371/journal.pone.0057152; PMCID=PMC3578816
Reuss D.E., Mucha J., Hagenlocher C., Ehemann V., Kluwe L., Mautner V.-F., von Deimling A.
Sensitivity of malignant peripheral nerve sheath tumor cells to TRAIL is augmented by loss of NF1 through modulation of MYC/MAD and is potentiated by curcumin through induction of ROS.
PLoS ONE 8:E57152-E57152(2013)

PubMed=28556483; DOI=10.1002/1878-0261.12086; PMCID=PMC5579334
Kolberg M., Bruun J., Murumagi A., Mpindi J.P., Bergsland C.H., Holand M., Eilertsen I.A., Danielsen S.A., Kallioniemi O.-P., Lothe R.A.
Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors.
Mol. Oncol. 11:1156-1171(2017)

PubMed=32642732; DOI=10.1093/noajnl/vdz049; PMCID=PMC7317054
Pemov A., Li H., Presley W., Wallace M.R., Miller D.T.
Genetics of human malignant peripheral nerve sheath tumors.
Neurooncol. Adv. 2:i50-i61(2020)